Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupIndolent LymphomasDiseaseChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaSubgroupICD10C91.1-MeSHSequenceOBIN(100/900/1000)/VNTC20, CLL, C1, first-line (PID1259) -|- C2 (PID1316) -|- C3-6 (PID1317) -|- maint. (PID1318)ChemotherapyChemo-substanceVenetoclaxChemo-substanceVenetoclaxChemo-substanceVenetoclaxChemo-substanceVenetoclaxNo. Substances1 RadiotherapySupportive therapySupportive substanceCotrimoxazoleSupportive substanceCotrimoxazoleSupportive substanceCotrimoxazoleSupportive substanceCotrimoxazoleNo. Substances1Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentiondisease controlRisksAnemia Hb below 8g/dlDiarrheaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaInfectionsNeutropeniaPneumoniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorFischer KDiseaseChronische lymphatische Leukämie, CD20+, ErstlinieOrigin CLL14 trial, Department I of Internal Medicine, Center of Integrated Oncology, University Hospital of CologneProtocols in Revision 1 protocol foundProtocols under revision.Obinutuzumab 1000 / Venetoclax 400 - Venetoclax 400, Chronic Lymphocytic Leukemia, maintenance, first-line (PID1318)